相关临床试验
163
27 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1837
进行中（未招募）
10
6.1%
已完成
68
41.7%
Enrolling By Invitation
2
1.2%
尚未招募
15
9.2%
招募中
37
22.7%
终止
4
2.5%
Unknown
27
16.6%
暂无批准数据
- A multinational randomized clinical trial demonstrates that precision immunotherapy tailored to patients' immune profiles significantly improved organ dysfunction in sepsis patients. - The ImmunoSep study enrolled 276 patients across six countries, stratifying them based on immune status into macrophage activation-like syndrome or sepsis-induced immunoparalysis groups. - Patients receiving targeted immunotherapy showed 35.1% improvement in organ dysfunction compared to 17.9% in placebo group, though 28-day mortality rates remained unchanged. - The precision approach represents a critical advancement over previous "one-size-fits-all" immunotherapy strategies that have repeatedly failed in sepsis treatment.
- A meta-analysis of 11 studies reveals that tenecteplase is associated with a higher likelihood of excellent recovery in ischemic stroke patients compared to alteplase. - Tenecteplase-treated patients showed a 5% greater chance of excellent functional outcome and a 10% reduced risk of disability three months post-stroke. - While both drugs demonstrate similar safety profiles and increase the chances of good recovery, tenecteplase presents a statistically significant advantage. - The findings support the potential shift towards tenecteplase as the preferred thrombolytic agent for acute ischemic stroke within the 4.5-hour window.
